Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fosphenytoin (Cerebyx)

T R Browne1

  • 1Department of Neurology, Boston University School of Medicine, Massachusetts, USA.

Clinical Neuropharmacology
|February 1, 1997
PubMed
Summary

Fosphenytoin, a phenytoin prodrug, offers improved solubility and absorption compared to standard injectable phenytoin. It demonstrates reduced local toxicity and similar systemic effects, making it a viable alternative for epilepsy treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epilepsy.

The New England journal of medicine·2001
Same author

Variable absorption of carbidopa affects both peripheral and central levodopa metabolism.

Journal of clinical pharmacology·2000
Same author

Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique.

Journal of clinical pharmacology·2000
Same author

Pharmacokinetics of antiepileptic drugs.

Neurology·1998
Same author

Intravenous phenytoin: cheap but not necessarily a bargain.

Neurology·1998
Same author

Performance of human mass balance studies with stable isotope-labeled drug and continuous flow-isotope ratio mass spectrometry: a progress report.

Journal of clinical pharmacology·1998

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Development

Background:

  • Standard injectable phenytoin has limitations including poor solubility and slower absorption.
  • Fosphenytoin was developed as a water-soluble prodrug to overcome these limitations.

Purpose of the Study:

  • To evaluate fosphenytoin as a safer and more effective alternative to injectable phenytoin.
  • To assess fosphenytoin's efficacy and safety in various clinical settings.

Main Methods:

  • Fosphenytoin's physicochemical properties (solubility, absorption) were compared to phenytoin.
  • Clinical trials assessed fosphenytoin for intramuscular maintenance dosing, intramuscular loading dose, and intravenous treatment of status epilepticus.
  • Local and systemic toxicity profiles were evaluated for both fosphenytoin and phenytoin.

Main Results:

  • Fosphenytoin exhibits superior aqueous solubility and rapid intramuscular absorption.
  • Successful clinical use was demonstrated for intramuscular maintenance and loading doses, and IV treatment of status epilepticus.
  • Fosphenytoin showed reduced local toxicity (pain, burning, itching) compared to phenytoin.
  • Systemic toxicity was similar, with less hypotension and more paresthesias observed with fosphenytoin.

Conclusions:

  • Fosphenytoin is a well-tolerated and effective alternative to injectable phenytoin.
  • Its improved pharmacokinetic profile and reduced local toxicity enhance patient care in epilepsy management.

Related Experiment Videos